243 related articles for article (PubMed ID: 11134190)
1. Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial.
Saarto T; Blomqvist C; Virkkunen P; Elomaa I
J Clin Oncol; 2001 Jan; 19(1):10-7. PubMed ID: 11134190
[TBL] [Abstract][Full Text] [Related]
2. Ten-year follow-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients.
Saarto T; Vehmanen L; Virkkunen P; Blomqvist C
Acta Oncol; 2004; 43(7):650-6. PubMed ID: 15545185
[TBL] [Abstract][Full Text] [Related]
3. Clodronate treatment influences MMP-2 associated outcome in node positive breast cancer.
Leppä S; Saarto T; Vehmanen L; Blomqvist C; Elomaa I
Breast Cancer Res Treat; 2005 Mar; 90(2):117-25. PubMed ID: 15803358
[TBL] [Abstract][Full Text] [Related]
4. Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer.
Powles T; Paterson S; Kanis JA; McCloskey E; Ashley S; Tidy A; Rosenqvist K; Smith I; Ottestad L; Legault S; Pajunen M; Nevantaus A; Männistö E; Suovuori A; Atula S; Nevalainen J; Pylkkänen L
J Clin Oncol; 2002 Aug; 20(15):3219-24. PubMed ID: 12149294
[TBL] [Abstract][Full Text] [Related]
5. Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026].
Powles T; Paterson A; McCloskey E; Schein P; Scheffler B; Tidy A; Ashley S; Smith I; Ottestad L; Kanis J
Breast Cancer Res; 2006; 8(2):R13. PubMed ID: 16542503
[TBL] [Abstract][Full Text] [Related]
6. Reduction in new metastases in breast cancer with adjuvant clodronate treatment.
Diel IJ; Solomayer EF; Costa SD; Gollan C; Goerner R; Wallwiener D; Kaufmann M; Bastert G
N Engl J Med; 1998 Aug; 339(6):357-63. PubMed ID: 9691101
[TBL] [Abstract][Full Text] [Related]
7. Three-year oral clodronate treatment does not impair mineralization of newly formed bone--a histomorphometric study.
Saarto T; Taube T; Blomqvist C; Vehmanen L; Elomaa I
Calcif Tissue Int; 2005 Aug; 77(2):84-90. PubMed ID: 16075363
[TBL] [Abstract][Full Text] [Related]
8. Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: a randomized study in premenopausal breast cancer patients.
Saarto T; Blomqvist C; Välimäki M; Mäkelä P; Sarna S; Elomaa I
J Clin Oncol; 1997 Apr; 15(4):1341-7. PubMed ID: 9193325
[TBL] [Abstract][Full Text] [Related]
9. Current and future status of adjuvant therapy for breast cancer.
Coleman RE
Cancer; 2003 Feb; 97(3 Suppl):880-6. PubMed ID: 12548590
[TBL] [Abstract][Full Text] [Related]
10. Ten-year follow-up of 3 years of oral adjuvant clodronate therapy shows significant prevention of osteoporosis in early-stage breast cancer.
Saarto T; Vehmanen L; Blomqvist C; Elomaa I
J Clin Oncol; 2008 Sep; 26(26):4289-95. PubMed ID: 18779616
[TBL] [Abstract][Full Text] [Related]
11. Should oral bisphosphonates be standard of care in women with early breast cancer?
Clemons M; Verma S
Breast Cancer Res Treat; 2005 Apr; 90(3):315-8. PubMed ID: 15830146
[TBL] [Abstract][Full Text] [Related]
12. Clodronate: a review of its use in breast cancer.
Hurst M; Noble S
Drugs Aging; 1999 Aug; 15(2):143-67. PubMed ID: 10495073
[TBL] [Abstract][Full Text] [Related]
13. Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trial.
Paterson AH; Anderson SJ; Lembersky BC; Fehrenbacher L; Falkson CI; King KM; Weir LM; Brufsky AM; Dakhil S; Lad T; Baez-Diaz L; Gralow JR; Robidoux A; Perez EA; Zheng P; Geyer CE; Swain SM; Costantino JP; Mamounas EP; Wolmark N
Lancet Oncol; 2012 Jul; 13(7):734-42. PubMed ID: 22704583
[TBL] [Abstract][Full Text] [Related]
14. Meta-analysis of clodronate and breast cancer survival.
Ha TC; Li H
Br J Cancer; 2007 Jun; 96(12):1796-801. PubMed ID: 17325699
[TBL] [Abstract][Full Text] [Related]
15. [Double-blinded controlled study comparing clodronate versus placebo in patients with breast cancer bone metastases].
Tubiana-Hulin M; Beuzeboc P; Mauriac L; Barbet N; Frenay M; Monnier A; Pion JM; Switsers O; Misset JL; Assadourian S; Bessa E
Bull Cancer; 2001 Jul; 88(7):701-7. PubMed ID: 11495824
[TBL] [Abstract][Full Text] [Related]
16. Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer.
Paterson AH; Powles TJ; Kanis JA; McCloskey E; Hanson J; Ashley S
J Clin Oncol; 1993 Jan; 11(1):59-65. PubMed ID: 8418243
[TBL] [Abstract][Full Text] [Related]
17. Clodronate : a review of its use in the prevention of bone metastases and the management of skeletal complications associated with bone metastases in patients with breast cancer.
Dando TM; Wiseman LR
Drugs Aging; 2004; 21(14):949-62. PubMed ID: 15554753
[TBL] [Abstract][Full Text] [Related]
18. [The role of adjuvant clodronate therapy for prevention of bone metastasis in breast cancer].
Horváth Z
Magy Onkol; 2002; 46(4):361-4. PubMed ID: 12563361
[TBL] [Abstract][Full Text] [Related]
19. Clodronate decreases the frequency of skeletal metastases in women with breast cancer.
Kanis JA; Powles T; Paterson AH; McCloskey EV; Ashley S
Bone; 1996 Dec; 19(6):663-7. PubMed ID: 8968035
[TBL] [Abstract][Full Text] [Related]
20. Phase III Randomized Trial of Bisphosphonates as Adjuvant Therapy in Breast Cancer: S0307.
Gralow JR; Barlow WE; Paterson AHG; M'iao JL; Lew DL; Stopeck AT; Hayes DF; Hershman DL; Schubert MM; Clemons M; Van Poznak CH; Dees EC; Ingle JN; Falkson CI; Elias AD; Messino MJ; Margolis JH; Dakhil SR; Chew HK; Dammann KZ; Abrams JS; Livingston RB; Hortobagyi GN
J Natl Cancer Inst; 2020 Jul; 112(7):698-707. PubMed ID: 31693129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
